Welcome to our dedicated page for Cytokinetics news (Ticker: CYTK), a resource for investors and traders seeking the latest updates and insights on Cytokinetics stock.
Cytokinetics Inc. (symbol: CYTK) is a leading biopharmaceutical company focused on the discovery, development, and commercialization of pioneering muscle activators. With a primary goal of addressing debilitating diseases where muscle performance is compromised, Cytokinetics is at the forefront of muscle biology research.
Specializing in muscle function and contractility, Cytokinetics has developed small molecule drug candidates aimed at enhancing muscle performance. The company’s innovative treatments target diseases such as amyotrophic lateral sclerosis (ALS), heart failure, spinal muscular atrophy (SMA), and chronic obstructive pulmonary diseases (COPD).
Some of the key investigational medicines in the pipeline include:
- CK-4021586 (CK-586): A cardiac myosin inhibitor showing promise in the treatment of cardiac diseases.
- Aficamten: Designed to improve heart muscle function in chronic heart failure patients.
- Omecamtiv Mecarbil: Another advanced therapy aimed at boosting heart muscle performance.
With a strong emphasis on improving the quality of life for patients with severe cardiovascular and neuromuscular diseases, Cytokinetics is committed to groundbreaking research and development. The company's strategic partnerships and collaborations support its mission to bring effective treatments to market, providing hope to patients worldwide.
Recently, Cytokinetics has been actively engaged in investor events and webcasts, sharing forward-looking statements and updates about its latest achievements and ongoing projects. The company's commitment to transparency and investor relations has established it as a reliable entity in the biopharmaceutical industry.
For more detailed updates and news, visit here, here, here, and here.
For investor inquiries, please contact Diane Weiser, Senior Vice President of Corporate Affairs, at (415) 290-7757.
Rhea-AI Summary
Cytokinetics, Incorporated (CYTK) will report fourth-quarter results on February 27, 2024, followed by a conference call to discuss operational and financial outcomes. The live webcast and telephonic access details are provided for interested participants.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.69%
Tags
-
Rhea-AI Summary
Cytokinetics, Incorporated (CYTK) President and CEO, Robert I. Blum, will participate in a virtual fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13, 2024. The live webcast can be accessed on the company's website, with a replay available for 90 days after the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.79%
Tags
-
Rhea-AI Summary
Cytokinetics, Incorporated (Nasdaq: CYTK) has announced the recipients of its sixth annual Communications Grant Program, awarding a total of $100,000 to five patient advocacy organizations. The grants, amounting to $20,000 each, are intended to support increased capacity in communications, awareness building, and community engagement for the hypertrophic cardiomyopathy (HCM), heart failure, and amyotrophic lateral sclerosis (ALS) communities. The grants will be utilized for projects aimed at increasing access to resources, expanding organizational reach, and launching educational programs. The recipients include the ALS Therapy Development Institute, the Hypertrophic Cardiomyopathy Association, and three other patient advocacy organizations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.32%
Tags
Rhea-AI Summary
Cytokinetics, Incorporated (Nasdaq: CYTK) announced new data at CMR 2024 demonstrating favorable effects on cardiac structure, function, and fibrosis related to treatment with aficamten in patients with hypertrophic cardiomyopathy (HCM). The data showed that treatment with aficamten for 48 weeks resulted in statistically significant improvements in measures of cardiac structure and function, including left ventricular mass index, maximum left ventricular septal wall thickness, left atrial volume, and mitral regurgitant volume and fraction. Additionally, treatment with aficamten stabilized interstitial and replacement myocardial fibrosis, with no increase in the fibrosis mass. These findings suggest potential disease-modifying effects of aficamten in patients with obstructive HCM.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.39%
Tags
-
Rhea-AI Summary
Cytokinetics, Incorporated (Nasdaq: CYTK) will present the Effect of Aficamten on Structure and Function in Patients with Obstructive Hypertrophic Cardiomyopathy at CMR 2024 in London, UK from January 25-27, 2024. The presentation will be conducted by Ahmad Masri, M.D., MS, Director of the Hypertrophic Cardiomyopathy Center at Oregon Health & Science University, during the Rapid Fire session on January 25, 2024, at 2:55 – 3:00 PM GMT.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.43%
Tags
-
Rhea-AI Summary
Cytokinetics, Incorporated (CYTK) granted 6,150 stock options to three new employees as a material inducement to their employment. The options have an exercise price of $83.49 per share, vest over 4 years, and have a 10-year term. This action was taken in accordance with Nasdaq Listing Rule 5635(c)(4).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.85%
Tags
Rhea-AI Summary
Cytokinetics, Incorporated (CYTK) to present at 42nd Annual J.P. Morgan Healthcare Conference. Robert I. Blum, President and CEO, to present on January 8, 2024. Webcast available on company website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3%
Tags
-
Rhea-AI Summary
Cytokinetics, Incorporated (Nasdaq: CYTK) announced positive topline results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM). The results show that treatment with aficamten significantly improved exercise capacity compared to placebo, with a statistically significant increase in peak oxygen uptake. The treatment effect was consistent across all prespecified subgroups. Statistically significant and clinically meaningful improvements were also observed in all 10 prespecified secondary endpoints. Aficamten was well-tolerated with an adverse event profile comparable to placebo. Core echocardiographic left ventricular ejection fraction (LVEF) was observed to be <50% in a small percentage of patients on aficamten, but there were no instances of worsening heart failure or treatment interruptions due to low LVEF.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
82.54%
Tags
-
Rhea-AI Summary
Cytokinetics, Incorporated (Nasdaq: CYTK) to discuss topline results from pivotal Phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
82.54%
Tags
Rhea-AI Summary
Cytokinetics, Incorporated (Nasdaq: CYTK) announced the discontinuation of the clinical trial for reldesemtiv, a potential treatment for ALS, due to lack of efficacy. The trial, COURAGE-ALS, did not show any effect on the primary endpoint of change from baseline in ALSFRS-R or key secondary endpoints. The development of reldesemtiv has been terminated, disappointing results for the company after more than a decade of pursuit.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.18%
Tags
FAQ
What is the current stock price of Cytokinetics (CYTK)?
The current stock price of Cytokinetics (CYTK) is $46 as of February 28, 2025.
What is the market cap of Cytokinetics (CYTK)?
The market cap of Cytokinetics (CYTK) is approximately 5.6B.
What does Cytokinetics Inc. specialize in?
Cytokinetics Inc. specializes in developing muscle activators for the treatment of diseases characterized by reduced muscle function, such as ALS and heart failure.
What are some key drug candidates being developed by Cytokinetics?
Key drug candidates include CK-4021586 (CK-586), Aficamten, and Omecamtiv Mecarbil, all aimed at enhancing muscle function and contractility.
Which diseases are targeted by Cytokinetics' treatments?
Cytokinetics' treatments target diseases like amyotrophic lateral sclerosis (ALS), heart failure, spinal muscular atrophy (SMA), and chronic obstructive pulmonary diseases (COPD).
What recent achievements has Cytokinetics announced?
Recent achievements include updates on CK-4021586 (CK-586), participation in investor events, and forward-looking statements on new developments.
How does Cytokinetics contribute to muscle biology research?
As a leader in muscle biology, Cytokinetics focuses on discovering and developing small molecule drugs designed to increase muscle function and contractility.
Who can be contacted for investor relations at Cytokinetics?
For investor relations, contact Diane Weiser, Senior Vice President of Corporate Affairs, at (415) 290-7757.
Where can I find more detailed updates and news about Cytokinetics?
More updates and news can be found on the GlobeNewswire website with provided links in the detailed company description.
What is the focus of Cytokinetics’ investigational medicines?
The focus is on muscle-directed medicines that potentially improve the health span of patients with severe cardiovascular and neuromuscular diseases.
What makes Cytokinetics' approach unique?
Cytokinetics' approach is unique due to its focus on muscle biology and the development of small molecule drugs specifically engineered to enhance muscle function.
What platforms does Cytokinetics use for investor communication?
Cytokinetics uses investor events, webcasts, and platforms like GlobeNewswire to communicate with investors.
Cytokinetics Inc
Nasdaq:CYTK
CYTK Rankings
CYTK Stock Data
5.60B
114.81M
0.54%
119.33%
11.89%
Biotechnology
Pharmaceutical Preparations
United States
SOUTH SAN FRANCISCO